Recombinant Human EPO

• Description:

  EPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of EPO comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of EPO is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behaviour of EPO in vivo. Non-glycosylated Epo has an extremely short biological half life. Recombinant Human EPO is a glycosylated protein that runs at approximately 35 kDa owing to its glycosylation.

• Gene Name:

  EPO

• Gene Aliases:

  Erythropoietin
  Recombinant Human Erythropoietin-Alpha (EPO)

• Gene ID:

  2056

• Accession Number:

  P01588

• Organism:

  Human

• Source:

  CHO

• Concentration:

  <1.0 EU/μg of recombinant protein as determined by the LAL method

• Purity:

  >95% as determined by SDS-PAGE

• Solubility:

  A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.

• Function:

  Activity was determined by the dose-dependent proliferation assay using a factor-dependent human erythroleukemic cell line TF-1 and was found to be less than 0.2ng/ml

• Molecular Weight:

  20

• Shipping Conditions:

  Ambient Temperature

• Storage Conditions:

  The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

• Appearance:

  Lyophilized Powder

• Formulation:

  Lyophilized from a 0.2 μm filtered solution in PBS (pH 7)

• CAS Number:

  9000-83-3